Dannielle Appelhans

Dannielle is the chief executive officer of COUR Pharmaceuticals, where she previously served as the company’s chief operating officer leading R&D, technical development, clinical operations, quality, technical operations, and playing a pivotal role in shaping corporate strategy. Before moving to COUR, Dannielle was chief executive officer of Rubius Therapeutics, Inc. She has also held multiple executive-level positions at Novartis, including as the global head of supply chain management, where she was responsible for the end-to-end supply chain of all Novartis divisions worldwide, culminating in her role as chief technical officer of Novartis Gene Therapies (formerly AveXis). Earlier in her career, Dannielle served as a Senior Engagement Manager at McKinsey & Company and held roles of increasing responsibility at Eli Lilly and Company. Dannielle earned a Master of Science in mechanical engineering from Massachusetts Institute of Technology’s School of Engineering, an MBA from Massachusetts Institute of Technology’s Sloan School of Management, and a Bachelor of Science in Engineering in mechanical engineering from the University of Michigan.